A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
NuCana plc
Formation Biologics
Numab Therapeutics AG
Turnstone Biologics, Corp.
Seagen Inc.
Sotio Biotech Inc.
Eisai Inc.
Atreca, Inc.
Fusion Pharmaceuticals Inc.
Fate Therapeutics
Genmab
Oncorus, Inc.
Nektar Therapeutics
Calithera Biosciences, Inc
Rubius Therapeutics
MacroGenics
Eli Lilly and Company
Incyte Corporation
Seagen Inc.
AIDS Malignancy Consortium
Seagen Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center